Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mirrabooka Investments Limited (MIR.AX)
Melbourne, VIC, AU
Mirrabooka Investments Limited functions as a publicly owned investment management entity. It primarily allocates capital within the public equity markets of Australia and New Zealand. The firm's approach is to identify value opportunities among small and mid-cap companies, specifically targeting those not ranking among the top 50 listed by market capitalization on the Australian Stock Exchange. Its portfolios are constructed through a disciplined, bottom-up stock-picking process, driven by fundamental analysis. Proprietary in-house research is further enriched by insights gained from external sources. Typically, investments are directed towards companies operating in the industrials, healthcare, banking, and materials sectors. Founded in April 1999, Mirrabooka Investments Limited is headquartered in Melbourne, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.67% | -1.61% | -5.79% | -12.86% | -23.03% | -21.29% | -24.69% | -11.91% | -27.16% | -10.95% | +157.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Asset Management: +17.4%-21.5% Q2'25: -22.5% (vs Q2'23)
-
EPS growth Asset Management: +22.7%-27.2% Q2'25: +14.3% (vs Q2'23)
-
FCF margin FCF growth · Asset Management: +27.7%+71.4% Q2'25: -30.9% (vs Q2'23)
-
EBIT margin Asset Management: +50.6%+71.4% ★ Q2'25: +67.9% (vs Q2'23)
-
ROIC Asset Management: +6.5%+1.4% Q2'25: +2.4% (vs Q2'23)
-
Share dilution Asset Management: +0.0%+1.5% Q2'25: +3.2% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Asset Management: -0.03×—
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrew J. Porter | Chief Financial Officer | — | male |
| Geoffrey N. Driver Ec | General Manager of Business Development & Investor Relations | — | male |
| Jaye Guy | Investment Analyst | — | male |
| Kieran Kennedy | Investment Analyst | — | male |
| Matthew John Rowe AGIA ACIS | Company Secretary | — | male |
| Robert Mark Freeman | MD, Chief Executive Officer & Director | — | male |
| Stuart Low | Investment Analyst | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MIR.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
